CA3020067A1 - Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative - Google Patents

Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative Download PDF

Info

Publication number
CA3020067A1
CA3020067A1 CA3020067A CA3020067A CA3020067A1 CA 3020067 A1 CA3020067 A1 CA 3020067A1 CA 3020067 A CA3020067 A CA 3020067A CA 3020067 A CA3020067 A CA 3020067A CA 3020067 A1 CA3020067 A1 CA 3020067A1
Authority
CA
Canada
Prior art keywords
bchl
agent
mdsc
pdt
vtp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3020067A
Other languages
English (en)
French (fr)
Inventor
Avigdor Scherz
Yoram Salomon
Lilach Agemy
Rachel HAMRI
Dina PREISE
Kwanghee Kim
Jonathan Coleman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Memorial Sloan Kettering Cancer Center
Original Assignee
Yeda Research and Development Co Ltd
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd, Memorial Sloan Kettering Cancer Center filed Critical Yeda Research and Development Co Ltd
Publication of CA3020067A1 publication Critical patent/CA3020067A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3020067A 2016-04-10 2017-04-10 Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative Pending CA3020067A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662320549P 2016-04-10 2016-04-10
US62/320,549 2016-04-10
PCT/IL2017/050440 WO2017179053A1 (en) 2016-04-10 2017-04-10 Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative

Publications (1)

Publication Number Publication Date
CA3020067A1 true CA3020067A1 (en) 2017-10-19

Family

ID=58794130

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3020067A Pending CA3020067A1 (en) 2016-04-10 2017-04-10 Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative

Country Status (14)

Country Link
US (2) US11278555B2 (https=)
EP (1) EP3442582A1 (https=)
JP (2) JP2019510807A (https=)
KR (2) KR20190008206A (https=)
CN (2) CN118304400A (https=)
AU (2) AU2017250732B2 (https=)
BR (1) BR112018070847A2 (https=)
CA (1) CA3020067A1 (https=)
IL (1) IL262191B2 (https=)
MX (2) MX390751B (https=)
RU (2) RU2021110230A (https=)
SG (1) SG11201808849TA (https=)
WO (1) WO2017179053A1 (https=)
ZA (1) ZA201807187B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10107240B2 (en) 2014-04-04 2018-10-23 Dayco Ip Holdings, Llc Check valves and Venturi devices having the same
CN106458190B (zh) 2014-05-30 2019-12-06 戴科知识产权控股有限责任公司 具有喷射器、气动控制阀和可选择的吸气器的真空创建系统
EP3723785A1 (en) * 2017-12-17 2020-10-21 Yeda Research and Development Co. Ltd Cop9 signalosome (csn) complex modulators and uses thereof
WO2022149934A1 (ko) * 2021-01-08 2022-07-14 가톨릭대학교 산학협력단 암세포의 항암 면역치료를 위한 항체-폴리에틸렌글리콜-광감각제 접합체

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE347554T1 (de) 1998-12-09 2006-12-15 Yeda Res & Dev Palladiumsubstituierte bakteriochlorophyllderivate und deren verwendung
IL133253A0 (en) * 1999-12-01 2001-04-30 Yeda Res & Dev Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them
IL152900A0 (en) * 2002-11-17 2003-06-24 Yeda Res & Dev Water-soluble bacteriochlorophyll derivatives and their pharmaceutical uses
PT2061512T (pt) 2006-08-23 2020-01-14 Yeda Res & Dev Conjugados de péptidos com rgd e fotossensibilizantes de (bacterio)clorofila e as suas utilizações
US8673270B2 (en) 2008-10-23 2014-03-18 Steba Biotech S.A. RGD-containing peptidomimetics and uses thereof
WO2012106343A2 (en) * 2011-02-01 2012-08-09 The Board Of Trustees Of The University Of Illinois Hdac inhibitors and therapeutic methods using the same
TWI442945B (zh) * 2011-05-18 2014-07-01 Univ Nat Taiwan 雙效微脂體用於治療的方法
WO2014141289A1 (en) * 2013-03-12 2014-09-18 Amrita Vishwa Vidyapeetham University Photo - chemo composition on the basis of microcapsules with a core -shell structure

Also Published As

Publication number Publication date
US20220202838A1 (en) 2022-06-30
AU2017250732B2 (en) 2022-11-10
WO2017179053A1 (en) 2017-10-19
MX2018012392A (es) 2019-08-21
IL262191B2 (en) 2025-01-01
RU2747258C2 (ru) 2021-04-29
IL262191B1 (en) 2024-09-01
ZA201807187B (en) 2020-01-29
RU2018139523A (ru) 2020-05-15
US11278555B2 (en) 2022-03-22
US20190125769A1 (en) 2019-05-02
EP3442582A1 (en) 2019-02-20
SG11201808849TA (en) 2018-11-29
MX2022003190A (es) 2022-04-11
CN109862918A (zh) 2019-06-07
KR20190008206A (ko) 2019-01-23
BR112018070847A2 (pt) 2019-02-05
RU2021110230A (ru) 2021-05-26
MX390751B (es) 2025-03-21
JP2022031823A (ja) 2022-02-22
AU2017250732A1 (en) 2018-11-15
IL262191A (en) 2018-11-29
CN118304400A (zh) 2024-07-09
JP2019510807A (ja) 2019-04-18
KR20220139445A (ko) 2022-10-14
AU2023200591A1 (en) 2023-03-09
RU2018139523A3 (https=) 2020-07-07

Similar Documents

Publication Publication Date Title
US20220202838A1 (en) Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative
Luo et al. Emerging strategies in cancer therapy combining chemotherapy with immunotherapy
Guan et al. A novel prodrug and its nanoformulation suppress cancer stem cells by inducing immunogenic cell death and inhibiting indoleamine 2, 3-dioxygenase
EP2944323B1 (en) Agents for treating tumours, use and method thereof
Chiang et al. Regorafenib enhances antitumor immune efficacy of anti-PD-L1 immunotherapy on oral squamous cell carcinoma
Liu et al. Advancing immune checkpoint blockade in colorectal cancer therapy with nanotechnology
FR2918279A1 (fr) Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
US20200377596A1 (en) Dosing of bispecific t cell engager
JP2023505303A (ja) 癌治療におけるｉｌ－１５及びｃｄ４０アゴニストの組合せ免疫療法
Camargo et al. Control of aggressive 4T1-luc metastatic breast cancer using Immunogenic cell lysates generated with methotrexate
Lobo Immunological Effects of Photodynamic Therapy
TWI798243B (zh) 治療癌症的方法
Lou Applications of porphyrin nanoparticles in enhancing Cancer immunotherapies
Hu et al. Perivascular delivery of photothermal-immunotherapy nanovaccine bypasses blood circulation to enhance the antitumor immune response of breast cancer
Zhao et al. Metabolic nanoblockers for synergistic cancer treatment through glutaminase inhibition and sonodynamic therapy
Hickstein et al. Prolonged survival of renal allograft in rats by methotrexate-albumin conjugates as immunosuppressive therapy
Li et al. Fluence rate differences in photodynamic therapy efficacy and activation of immune checkpoints of murine colorectal cancer
Wang et al. Reprogramming Chemoimmunotherapy via Biomimetic Cell Membrane-Clay Platform to Amplify Prime–Boost Antitumor Immunity
US20230149547A1 (en) Reduced caloric intake and immunotherapy for the treatment of cancer
WO2023203561A1 (en) Apoptotic cell - check point inhibitor combination therapy
Caccia Prolonged contact with dendritic cells turns lymph node‐resident NK cells into anti‐tumor effectors
Peng et al. Engineering selenium-loaded NK–bacterial hybrid vesicle activate innate and adaptive immunity for triple-negative breast cancer therapy
Ratain et al. 388 Imetelstat sodium (GRN163L), a telomerase inhibitor: tolerability, pharmacokinetics and pharmacodynamic activity using an intermittent once every four weeks dosing schedule in patients with advanced solid tumors
Hamri Targeting the microenvironment of 4T1 tumors using RGD-conjugated bacteriochlorophylls as a theranostic tool
US20200030375A1 (en) Therapy and methods of introducing immature dendritic cells and/or cytoxic t lymphocyte and anti pd-1 / pd-l1 antibody for treatment of tumors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220405

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NOTICE OF ALLOWANCE IS ISSUED

Effective date: 20250522

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250522

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250522

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250925

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251125